Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, 215123, China.
Department of Gastrointestinal Medicine, The First Affiliated Hospital of Soochow University, Suzhou, 215123, China.
Obes Surg. 2021 Sep;31(9):4083-4092. doi: 10.1007/s11695-021-05520-9. Epub 2021 Jul 10.
Bariatric surgery has been applied for weight loss and comorbidity control in China since 2000. Recent studies have shown positive results for bariatric surgery in patients with a body mass index (BMI) of less than 35 kg/m. However, the effect of surgery on Chinese patients with type II diabetes mellitus (T2DM) has not yet been systematically investigated.
A comprehensive literature search was performed in the Cochrane Library, Embase, PubMed, and Web of Science from January 2014 to March 2020. All studies examined bariatric surgery outcomes on Chinese patients at 12-, 36-, and 60-month follow-up. The research followed the guidance of Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) recommendations.
Eleven studies containing 611 patients were included in this meta-analysis. Clinical indices at 12-, 36-, and 60-month follow-up were analyzed. Significant decreases were identified in body weight, BMI, waist circumference (WC), blood pressure (BP), fasting plasma glucose (FPG), glycosylated hemoglobin A1c (hemoglobin A1c, or HbA1c), triglyceride (TG), low-density lipoprotein (LDL), and high-density lipoprotein (HDL) postoperatively. An increasing trend in the T2DM remission rate was discovered. The remission group was observed to have significantly lower HbA1c and C-peptide level, a shorter duration of T2DM, and a higher BMI than the nonremission group at 12 months.
Bariatric surgery successfully provided significant BMI control as well as a reduction and normalization of glucose- and lipid-related metabolism at 12, 36, and 60 months postoperatively in Chinese patients with T2DM with a preoperative BMI of less than 35 kg/m. An increasing trend in the T2DM remission rate suggested promising future applications in this population.
自 2000 年以来,减重手术已在中国用于减肥和控制合并症。最近的研究表明,对于 BMI 低于 35kg/m 的患者,减重手术效果良好。然而,手术对中国 2 型糖尿病(T2DM)患者的影响尚未得到系统研究。
从 2014 年 1 月至 2020 年 3 月,我们在 Cochrane Library、Embase、PubMed 和 Web of Science 中进行了全面的文献检索。所有研究都检查了 12、36 和 60 个月随访时中国患者接受减重手术后的结果。研究遵循系统评价和荟萃分析报告的首选项目(PRISMA-P)建议的指导。
纳入了这项荟萃分析的 11 项研究共 611 例患者。分析了 12、36 和 60 个月随访时的临床指标。术后体重、BMI、腰围(WC)、血压(BP)、空腹血糖(FPG)、糖化血红蛋白 A1c(血红蛋白 A1c 或 HbA1c)、甘油三酯(TG)、低密度脂蛋白(LDL)和高密度脂蛋白(HDL)均显著降低。发现 T2DM 缓解率呈上升趋势。在 12 个月时,缓解组的 HbA1c 和 C 肽水平明显较低,T2DM 病程较短,BMI 较高,而非缓解组的 HbA1c 和 C 肽水平较高,T2DM 病程较长,BMI 较低。
对于术前 BMI 低于 35kg/m 的中国 T2DM 患者,减重手术后 12、36 和 60 个月,BMI 控制良好,血糖和血脂相关代谢得到改善和正常化。T2DM 缓解率呈上升趋势,这表明该人群有很好的应用前景。